Calprotectin in pregnancy and pregnancy-associated diseases: a systematic review and prospective cohort study.

Authors:
Timm Westhoff
Timm Westhoff
Universitätsklinikum Benjamin Franklin
Germany
Clemens B Tempfer
Clemens B Tempfer
Ruhr University Bochum

Arch Gynecol Obstet 2019 Jun 5;299(6):1567-1577. Epub 2019 Apr 5.

Department of Obstetrics and Gynecology, Ruhr-Universität Bochum - Marien Hospital Herne, Hölkeskampring 40, 44625, Herne, Germany.

Purpose: Calprotectin, a marker of acute and chronic inflammation, may play a role in pregnancy-associated disorders. We aimed to summarize available clinical data on calprotectin in pregnancy and to establish normal values of calprotectin during the course of pregnancy.

Methods: We performed a systematic review of the databases PubMed and Cochrane Central Register of Controlled Trials to identify experimental and clinical evidence assessing the role of calprotectin in pregnancy. In addition, we performed a prospective cohort study assessing serum and urine calprotectin throughout pregnancy.

Results: We identified 17 studies investigating 1638 pregnant women, 151 newborns, and 99 non-pregnant controls, measuring calprotectin in different compartments. Calprotectin was present in meconium and elevated in fecal samples of pregnant women with active inflammatory bowel disease. In women with pregnancy-induced hypertension, mild and severe preeclampsia (PE), calprotectin was significantly elevated in maternal plasma and serum, but not in fetal serum, amniotic fluid, and umbilical cord blood. For the cohort study, we recruited 196 pregnant women. PE and concomitant renal disease were present in 6/196 (3%) and 11/196 (5.6%) of women, respectively. Throughout pregnancy, median serum and urine levels of calprotectin largely exceed reported concentrations of the healthy non-pregnant population, but showed no significant variations between trimesters 1-3 and post-partum. Calprotectin in serum was correlated with systolic blood pressure and in urine with leukocytes and total protein. No significant differences were found in subgroup analyses of smokers vs. non-smokers, PE vs. none, and renal disease (kidney stones, reflux) vs. none.

Conclusion: Calprotectin concentrations in amnion fluid and stools serve as potential indicators of inflammatory states during pregnancy. Urinary calprotectin concentrations are continuously high during pregnancy and show no significant variations between trimesters 1-3 and post-partum.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00404-019-05134-8DOI Listing

Still can't find the full text of the article?

We can help you send a request to the authors directly.
June 2019
3 Reads

Publication Analysis

Top Keywords

calprotectin
13
calprotectin pregnancy
12
cohort study
12
pregnant women
12
variations trimesters
8
trimesters 1-3
8
systematic review
8
renal disease
8
calprotectin concentrations
8
prospective cohort
8
serum urine
8
1-3 post-partum
8
serum
5
women
5
pregnancy
5
newborns non-pregnant
4
exceed reported
4
compartments calprotectin
4
median serum
4
151 newborns
4

References

(Supplied by CrossRef)
Article in Biochem Pharmacol
C Gebhardt et al.
Biochem Pharmacol 2006
Article in PLoS One
AR Bourgonje et al.
PLoS One 2018
Article in Vet Immunol Immunopathol
M Koy et al.
Vet Immunol Immunopathol 2013
Article in Adv Exp Med Biol
P Brandtzaeg et al.
Adv Exp Med Biol 1995
Article in Inflamm Res
F Shabani et al.
Inflamm Res 2018
Article in BMC Pediatr
N Rumman et al.
BMC Pediatr 2014
Article in J Rheumatol
G Ferrara et al.
J Rheumatol 2018
Article in J Gastrointest Liver Dis
T Rokkas et al.
J Gastrointest Liver Dis 2018
Article in Postgrad Med
S-C Bae et al.
Postgrad Med 2017
Article in Clin J Am Soc Nephrol
F Heller et al.
Clin J Am Soc Nephrol 2011
Article in Pediatr Nephrol
JH Westhoff et al.
Pediatr Nephrol 2016

Similar Publications